JP6389194B2 - ナトリウムチャネルの調節剤としてのピリドンアミド - Google Patents

ナトリウムチャネルの調節剤としてのピリドンアミド Download PDF

Info

Publication number
JP6389194B2
JP6389194B2 JP2015556109A JP2015556109A JP6389194B2 JP 6389194 B2 JP6389194 B2 JP 6389194B2 JP 2015556109 A JP2015556109 A JP 2015556109A JP 2015556109 A JP2015556109 A JP 2015556109A JP 6389194 B2 JP6389194 B2 JP 6389194B2
Authority
JP
Japan
Prior art keywords
oxo
dihydropyridin
benzamide
trifluoromethyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015556109A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016506963A5 (cg-RX-API-DMAC7.html
JP2016506963A (ja
Inventor
サラ サビナ ハディダ−ルアー，
サラ サビナ ハディダ−ルアー，
コーリー アンダーソン，
コーリー アンダーソン，
ビジャヤラクスミ アルムガム，
ビジャヤラクスミ アルムガム，
イウリアナ ルチ アスギアン，
イウリアナ ルチ アスギアン，
ブライアン リチャード ベアー，
ブライアン リチャード ベアー，
アンドレアス ピー． テルミン，
アンドレアス ピー． テルミン，
ジェイムズ フィリップ ジョンソン，
ジェイムズ フィリップ ジョンソン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2016506963A publication Critical patent/JP2016506963A/ja
Publication of JP2016506963A5 publication Critical patent/JP2016506963A5/ja
Application granted granted Critical
Publication of JP6389194B2 publication Critical patent/JP6389194B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C07C63/06—Benzoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Ink Jet (AREA)
JP2015556109A 2013-01-31 2014-01-29 ナトリウムチャネルの調節剤としてのピリドンアミド Active JP6389194B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361759059P 2013-01-31 2013-01-31
US61/759,059 2013-01-31
PCT/US2014/013652 WO2014120808A1 (en) 2013-01-31 2014-01-29 Pyridone amides as modulators of sodium channels

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018027902A Division JP6741704B2 (ja) 2013-01-31 2018-02-20 ナトリウムチャネルの調節剤としてのピリドンアミド

Publications (3)

Publication Number Publication Date
JP2016506963A JP2016506963A (ja) 2016-03-07
JP2016506963A5 JP2016506963A5 (cg-RX-API-DMAC7.html) 2017-03-09
JP6389194B2 true JP6389194B2 (ja) 2018-09-12

Family

ID=50073531

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015556109A Active JP6389194B2 (ja) 2013-01-31 2014-01-29 ナトリウムチャネルの調節剤としてのピリドンアミド
JP2018027902A Active JP6741704B2 (ja) 2013-01-31 2018-02-20 ナトリウムチャネルの調節剤としてのピリドンアミド
JP2019056505A Withdrawn JP2019089861A (ja) 2013-01-31 2019-03-25 ナトリウムチャネルの調節剤としてのピリドンアミド
JP2020169731A Pending JP2021001232A (ja) 2013-01-31 2020-10-07 ナトリウムチャネルの調節剤としてのピリドンアミド

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018027902A Active JP6741704B2 (ja) 2013-01-31 2018-02-20 ナトリウムチャネルの調節剤としてのピリドンアミド
JP2019056505A Withdrawn JP2019089861A (ja) 2013-01-31 2019-03-25 ナトリウムチャネルの調節剤としてのピリドンアミド
JP2020169731A Pending JP2021001232A (ja) 2013-01-31 2020-10-07 ナトリウムチャネルの調節剤としてのピリドンアミド

Country Status (34)

Country Link
US (6) US9051270B2 (cg-RX-API-DMAC7.html)
EP (3) EP2953931B1 (cg-RX-API-DMAC7.html)
JP (4) JP6389194B2 (cg-RX-API-DMAC7.html)
KR (2) KR102227592B1 (cg-RX-API-DMAC7.html)
CN (2) CN108164457B (cg-RX-API-DMAC7.html)
AP (1) AP2015008633A0 (cg-RX-API-DMAC7.html)
AR (1) AR094667A1 (cg-RX-API-DMAC7.html)
AU (3) AU2014212509B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015018289A2 (cg-RX-API-DMAC7.html)
CA (1) CA2898866C (cg-RX-API-DMAC7.html)
CL (1) CL2015002147A1 (cg-RX-API-DMAC7.html)
CY (1) CY1119163T1 (cg-RX-API-DMAC7.html)
DK (2) DK2953931T3 (cg-RX-API-DMAC7.html)
ES (2) ES2626555T3 (cg-RX-API-DMAC7.html)
GE (2) GEP20207177B (cg-RX-API-DMAC7.html)
HR (2) HRP20170787T1 (cg-RX-API-DMAC7.html)
HU (2) HUE053448T2 (cg-RX-API-DMAC7.html)
IL (2) IL269964B1 (cg-RX-API-DMAC7.html)
LT (2) LT3239134T (cg-RX-API-DMAC7.html)
MX (2) MX2021003687A (cg-RX-API-DMAC7.html)
NZ (2) NZ710270A (cg-RX-API-DMAC7.html)
PE (2) PE20151781A1 (cg-RX-API-DMAC7.html)
PH (1) PH12015501661B1 (cg-RX-API-DMAC7.html)
PL (2) PL3239134T3 (cg-RX-API-DMAC7.html)
PT (2) PT3239134T (cg-RX-API-DMAC7.html)
RS (2) RS61503B1 (cg-RX-API-DMAC7.html)
RU (1) RU2662223C2 (cg-RX-API-DMAC7.html)
SG (2) SG10201706206PA (cg-RX-API-DMAC7.html)
SI (2) SI3239134T1 (cg-RX-API-DMAC7.html)
SM (2) SMT202100030T1 (cg-RX-API-DMAC7.html)
TW (2) TWI655187B (cg-RX-API-DMAC7.html)
UA (1) UA120589C2 (cg-RX-API-DMAC7.html)
UY (1) UY35288A (cg-RX-API-DMAC7.html)
WO (1) WO2014120808A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11673864B2 (en) 2013-01-31 2023-06-13 Vertex Pharmaceuticals Incorporated Pyridone amides as modulators of sodium channels

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104093716B (zh) 2011-10-31 2017-06-23 克赛农制药股份有限公司 联芳醚磺酰胺化合物及其作为治疗剂的用途
EP2773637B1 (en) 2011-10-31 2016-06-08 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
CA2874621A1 (en) 2012-05-22 2013-11-28 Genentech, Inc. N-substituted benzamides and their use in the treatment of pain
BR112015000187A2 (pt) 2012-07-06 2017-06-27 Genentech Inc benzamidas substituídas com n e métodos de uso das mesmas
AR095192A1 (es) 2013-01-31 2015-09-30 Vertex Pharma Quinolina y quinazolinamidas como modulares de canales de sodio
WO2014153037A1 (en) 2013-03-14 2014-09-25 Genentech, Inc. Substituted triazolopyridines and methods of use thereof
US9493429B2 (en) 2013-03-15 2016-11-15 Genentech, Inc. Substituted benzoxazoles and methods of use thereof
CA2918365C (en) 2013-07-19 2021-09-07 Vertex Pharmaceuticals Incorporated Sulfonamides as modulators of sodium channels
MX2016006936A (es) 2013-11-27 2016-10-05 Genentech Inc Benzamidas sustituidas y metodos para usarlas.
UA121379C2 (uk) 2013-12-13 2020-05-25 Вертекс Фармасьютикалз Інкорпорейтед Проліки піридонамідів, застосовувані як модулятори натрієвих каналів
CN106715418A (zh) 2014-07-07 2017-05-24 基因泰克公司 治疗化合物及其使用方法
BR112017024853A2 (pt) 2015-05-22 2018-08-07 Genentech Inc composto, composição farmacêutica, método para tratar uma doença ou condição em um mamífero, para tratamento de prurido em um mamífero, para tratamento ou profilaxia e uso de um composto
JP2018526371A (ja) 2015-08-27 2018-09-13 ジェネンテック， インコーポレイテッド 治療化合物及びその使用方法
BR112018006189A2 (pt) 2015-09-28 2018-10-09 Genentech Inc compostos da fórmula, composição farmacêutica, métodos de tratamento de uma doença, de diminuição do fluxo de íons e de tratamento de prurido em um mamífero, método para tratamento de dores em um mamífero e uso de um composto
CN108495851A (zh) 2015-11-25 2018-09-04 基因泰克公司 取代的苯甲酰胺及其使用方法
KR20180134860A (ko) 2016-02-15 2018-12-19 체엠엠 - 포르슝스첸트룸 퓨어 몰레쿨라레 메디친 게엠베하 암의 치료를 위한 taf1 억제제
WO2017147147A1 (en) * 2016-02-23 2017-08-31 PixarBio Corporation Compositions comprising nav1.7 selective inhibitors for treating acute, post-operative, or chronic pain and methods of using the same
WO2017172802A1 (en) 2016-03-30 2017-10-05 Genentech, Inc. Substituted benzamides and methods of use thereof
MA46546A (fr) 2016-10-17 2021-05-05 Genentech Inc Composés thérapeutiques et leurs procédés d'utilisation
JP2020511511A (ja) 2017-03-24 2020-04-16 ジェネンテック， インコーポレイテッド ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体
JP7104070B2 (ja) 2017-05-16 2022-07-20 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルの調節因子としての重水素化ピリドンアミドおよびそのプロドラッグ
ES3008911T3 (en) 2017-07-11 2025-03-25 Vertex Pharma Carboxamides as modulators of sodium channels
US20190343817A1 (en) 2018-02-12 2019-11-14 Vertex Pharmaceuticals Incorporated Method of treating pain
JP2021514980A (ja) 2018-02-26 2021-06-17 ジェネンテック， インコーポレイテッド 疼痛及び関連病態に対するピリジン−スルホンアミド化合物及びその使用
JP2021519788A (ja) 2018-03-30 2021-08-12 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ナトリウムチャネル阻害剤としての縮合環ヒドロピリド化合物
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
JOP20210097A1 (ar) * 2018-11-02 2023-01-30 Merck Sharp & Dohme مركبات 2-أمينو-n-أريل غير متجانس-نيكوتيناميد كمثبطات nav1.8
EP3873468A4 (en) 2018-11-02 2022-10-26 Merck Sharp & Dohme LLC 2-AMINO-N-PHENYL-NICOTINAMIDES AS NAV1.8 INHIBITORS
CA3125244A1 (en) * 2019-01-04 2020-07-09 Jiangsu Hengrui Medicine Co., Ltd. 6-oxo-1,6-dihydropyridazine derivative, preparation method therefor and medical use thereof
WO2020146612A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
US12441703B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
CN112996774B (zh) * 2019-01-25 2022-11-22 江苏恒瑞医药股份有限公司 2-氧代-1,2-二氢吡啶类衍生物、其制备方法及其在医药上的应用
US20220162169A1 (en) * 2019-02-20 2022-05-26 Jiangsu Hengrui Medicine Co., Ltd. 6-oxo-1,6-dihydropyridazine prodrug derivative, preparation method therefor, and application thereof in medicine
WO2020176763A1 (en) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Dosage form comprising prodrug of na 1.8 sodium channel inhibitor
WO2020219867A1 (en) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Pyridone amide co-crystal compositions for the treatment of pain
WO2021018165A1 (zh) * 2019-07-30 2021-02-04 江苏恒瑞医药股份有限公司 吡啶苯甲酰胺类衍生物、其制备方法及其在医药上的应用
CN112390745B (zh) * 2019-08-19 2022-10-21 江苏恒瑞医药股份有限公司 吡啶烟酰胺类衍生物、其制备方法及其在医药上的应用
TW202115038A (zh) * 2019-08-19 2021-04-16 大陸商江蘇恆瑞醫藥股份有限公司 苯甲醯胺稠芳環類衍生物、其製備方法及其在醫藥上的應用
JP2022548104A (ja) * 2019-09-12 2022-11-16 オリオン コーポレーション ピリジン窒素酸化物及びその製造方法と使用
SI4069691T1 (sl) 2019-12-06 2025-02-28 Vertex Pharmaceuticals Incorporated Substituirani tetrahidrofurani kot modulatorji natrijevih kanalčkov
CN113045487B (zh) * 2019-12-27 2025-01-17 明慧医药（上海）有限公司 一种选择性钠通道调节剂及其制备和应用
CN114437062B (zh) * 2020-04-30 2024-05-17 成都海博为药业有限公司 一种可作为钠通道调节剂的化合物及其用途
MX2022015581A (es) 2020-06-17 2023-01-24 Merck Sharp & Dohme Llc 2-oxoimidazolidin-4-carboxamidas como inhibidores de nav1.8.
CN113880771B (zh) * 2020-07-03 2023-09-19 福建盛迪医药有限公司 一种选择性Nav抑制剂的结晶形式及其制备方法
CN111808019B (zh) * 2020-09-08 2020-11-27 上海济煜医药科技有限公司 一种并环化合物及其应用
CN114031518B (zh) 2020-12-08 2023-08-18 成都海博为药业有限公司 一种苄胺或苄醇衍生物及其用途
BR112023023239A2 (pt) 2021-05-07 2024-01-23 Merck Sharp & Dohme Llc Carboxamidas de cicloalquil 3-oxopiperazina e carboxamidas de cicloheteroalquil 3-oxopiperazina como inibidores de nav1.8
CN117794918A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 经取代的四氢呋喃类似物作为钠通道调节剂
CA3221960A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
WO2022256679A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
US20240285596A1 (en) 2021-06-04 2024-08-29 Vertex Pharmaceuticals Incorporated Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide
EP4347031B1 (en) 2021-06-04 2025-10-29 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
JP2024520648A (ja) 2021-06-04 2024-05-24 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルの調節因子としての置換テトラヒドロフラン－２－カルボキサミド
UY39881A (es) 2021-08-02 2023-06-15 Eurofarma Laboratorios S A “COMPUESTOS N-ACILHIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS”
UY39882A (es) 2021-08-02 2023-06-15 Eurofarma Laboratorios S A COMPUESTOS NACILHIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS
CN116655497B (zh) * 2022-02-25 2025-06-03 中国科学院上海药物研究所 脒类衍生化合物及其制备方法和用途
AU2023257313A1 (en) 2022-04-22 2024-10-31 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
CN119487003A (zh) 2022-04-22 2025-02-18 沃泰克斯药物股份有限公司 用于治疗疼痛的杂芳基化合物
EP4511114A1 (en) 2022-04-22 2025-02-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
CR20240513A (es) 2022-04-22 2025-04-30 Vertex Pharma Compuestos de heteroarilo para el tratamiento del dolor
KR20250006217A (ko) 2022-04-25 2025-01-10 사이트원 테라퓨틱스, 인코포레이티드 통증 치료를 위한 Naν1.8의 바이사이클릭 헤테로사이클릭 아미드 억제제
CN116947713A (zh) * 2022-04-25 2023-10-27 中国科学院上海药物研究所 并环类化合物及其应用
EP4630405A1 (en) 2022-12-06 2025-10-15 Vertex Pharmaceuticals Incorporated Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels
EP4660184A1 (en) 2023-01-30 2025-12-10 Eurofarma Laboratórios S.A. Nav1.7- and/or nav1.8-inhibiting hydroxamates, processes for the preparation thereof, compositions, uses, methods for treatment using same, and kits
AR131658A1 (es) 2023-01-30 2025-04-16 Eurofarma Laboratorios S A Hidrazidas bloqueadoras de nav 1.7 y/o nav 1.8, sus procesos de obtención, composiciones, usos, métodos de tratamiento de los mismos y sus kits
WO2024159285A1 (pt) 2023-01-30 2024-08-08 Eurofarma Laboratórios S.A. Compostos aril piridinas bloqueadores de nav 1.7 e/ou nav 1.8, seus processos de obtenção, composições, usos, métodos de tratamento destes e kits
AR131690A1 (es) 2023-01-30 2025-04-23 Eurofarma Laboratorios S A COMPUESTOS FENÓLICOS BLOQUEADORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, SUS COMPOSICIONES, SUS USOS, LOS MÉTODOS DE TRATAMIENTO DE LOS MISMOS Y LOS KITS
AR131715A1 (es) 2023-01-30 2025-04-23 Eurofarma Laboratorios S A AMIDAS BLOQUEADORAS DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE LOS MISMOS Y KITS
CN118324743A (zh) 2023-04-19 2024-07-12 中国科学院上海药物研究所 Nav1.8抑制剂及其制备方法和用途
WO2025090516A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing compounds for treating pain and solid forms thereof
WO2025090480A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
TW202535867A (zh) 2023-10-23 2025-09-16 美商維泰克斯製藥公司 用於治療疼痛之鈉通道調節劑及其固體形式的製備方法
TW202523313A (zh) 2023-10-23 2025-06-16 美商維泰克斯製藥公司 用於治療疼痛之雜芳基化合物
US20250186419A1 (en) 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Dosing regimens for treating pain
WO2025160286A1 (en) 2024-01-24 2025-07-31 Siteone Therapeutics, Inc. 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH598252A5 (cg-RX-API-DMAC7.html) * 1974-01-04 1978-04-28 Hoffmann La Roche
GB1447583A (en) * 1974-02-04 1976-08-25 Ici Ltd Xanthene derivatives
US4086350A (en) * 1974-11-06 1978-04-25 Smithkline Corporation Pharmaceutical compositions and method of producing anti-psychotic activity without extrapyramidal symptoms
GB1543964A (en) * 1976-04-08 1979-04-11 Ici Ltd Method of antagonising herbicides on soyabean and cotton
US5281620A (en) * 1986-12-23 1994-01-25 Cancer Research Campaign Technology Limited Compounds having antitumor and antibacterial properties
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
JP3285391B2 (ja) * 1992-09-01 2002-05-27 日本化学工業株式会社 ２−フェノキシ安息香酸の製造法
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
AU7712000A (en) 1999-09-24 2001-04-24 Johns Hopkins University School Of Medicine, The Methods for identifying an agent that corrects defective protein folding
JP2003034671A (ja) * 2001-05-17 2003-02-07 Nippon Nohyaku Co Ltd ベンズアミド誘導体及び農園芸用薬剤並びにその使用方法
DE60330126D1 (de) 2002-02-14 2009-12-31 Pharmacia Corp Substituierte pyridinone als modulatoren für p38 map kinase
CA2539227A1 (en) * 2003-08-08 2005-02-17 Vertex Pharmaceuticals Incorporated Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
KR100747401B1 (ko) * 2003-09-03 2007-08-08 화이자 인코포레이티드 프로스타글란딘 ｅ2 길항제로서의 페닐 또는 피리딜 아미드 화합물
BRPI0513717A (pt) 2004-07-23 2008-05-13 Pfizer derivados de piridina
MX2007015726A (es) 2005-06-09 2008-03-04 Vertex Pharma Derivados de indano como moduladores de canales ionicos.
CA2622076A1 (en) 2005-09-09 2007-03-15 Vertex Pharmaceuticals Incorporated Bicyclic derivatives as modulators of voltage gated ion channels
WO2007047474A2 (en) 2005-10-12 2007-04-26 Vertex Pharmaceuticals Incorporated Biphenyl derivatives as modulators of voltage gated ion channels
MX2008013194A (es) * 2006-04-11 2008-12-01 Vertex Pharma Composiciones utiles como inhibidores de canales de sodio regulados por voltaje.
EA015952B1 (ru) 2007-05-03 2011-12-30 Пфайзер Лимитед 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов
CA2687764A1 (en) 2007-05-25 2008-12-04 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
US8779197B2 (en) * 2007-10-11 2014-07-15 Vertex Pharmaceuticals Incorporated Aryl amides useful as inhibitors of voltage-gated sodium channels
WO2009049181A1 (en) * 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Amides useful as inhibitors of voltage-gated sodium channels
US8519137B2 (en) 2007-10-11 2013-08-27 Vertex Pharmaceuticals Incorporated Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
JP5552430B2 (ja) * 2007-10-31 2014-07-16 メルク・シャープ・アンド・ドーム・コーポレーション 疼痛の治療用としてのｐ２ｘ３受容体アンタゴニスト
JP5405592B2 (ja) 2008-12-23 2014-02-05 エフ．ホフマン−ラ ロシュ アーゲー Ｐ２ｘ７モジュレーターとしてのジヒドロピリドンアミド
EP2435407B1 (en) * 2009-05-29 2019-12-25 RaQualia Pharma Inc. Aryl substituted carboxamide derivatives as calcium or sodium channel blockers
TW201103904A (en) * 2009-06-11 2011-02-01 Hoffmann La Roche Janus kinase inhibitor compounds and methods
US8883782B2 (en) * 2010-03-15 2014-11-11 Amgen Inc. Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use
EP2595989B1 (en) 2010-05-06 2016-07-13 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
US8999967B2 (en) * 2010-09-29 2015-04-07 Presidio Pharmaceuticals, Inc. Tricyclic fused ring inhibitors of hepatitis C
PL2670752T3 (pl) 2011-02-02 2016-09-30 Pirolopirazynowe spirocykliczne piperydynoamidy jako modulatory kanałów jonowych
EP2675810A1 (en) * 2011-02-15 2013-12-25 Amgen Inc. Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
MX2013009393A (es) 2011-02-18 2013-08-29 Vertex Pharma Piperidinamidas cromano-espirociclicas como moduladores de canales de iones.
ES2618929T3 (es) 2011-03-14 2017-06-22 Vertex Pharmaceuticals Incorporated Morfolina-Spiro piperidina amida cíclica como moduladores del canal iónico
WO2012122716A1 (en) * 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases
US20120252852A1 (en) * 2011-03-29 2012-10-04 Sanofi Otamixaban formulations with improved stability
WO2013021535A1 (ja) 2011-08-10 2013-02-14 三菱電機株式会社 誘導加熱調理器及びそのプログラム
CN102584774B (zh) * 2011-12-22 2014-08-06 合肥工业大学 一种呫吨酮类衍生物及其用途
ME02630B (me) 2012-03-06 2017-06-20 Pfizer Makrociklički derivati, namijenjeni liječenju proliferativnih bolesti
CN102659628B (zh) * 2012-04-26 2014-07-02 四川大学 含芳酰胺的邻苯二甲腈单体及其合成方法和用其固化制备的聚邻苯二甲腈树脂
AR094667A1 (es) 2013-01-31 2015-08-19 Vertex Pharma Piridonamidas como moduladores de canales de sodio
US9108903B2 (en) 2013-01-31 2015-08-18 Vertex Pharmaceuticals Incorporated Amides as modulators of sodium channels
TWI606048B (zh) 2013-01-31 2017-11-21 帝人製藥股份有限公司 唑苯衍生物
AR095192A1 (es) 2013-01-31 2015-09-30 Vertex Pharma Quinolina y quinazolinamidas como modulares de canales de sodio
CA2918365C (en) 2013-07-19 2021-09-07 Vertex Pharmaceuticals Incorporated Sulfonamides as modulators of sodium channels
UA121379C2 (uk) 2013-12-13 2020-05-25 Вертекс Фармасьютикалз Інкорпорейтед Проліки піридонамідів, застосовувані як модулятори натрієвих каналів
ES3008911T3 (en) 2017-07-11 2025-03-25 Vertex Pharma Carboxamides as modulators of sodium channels
US20190343817A1 (en) 2018-02-12 2019-11-14 Vertex Pharmaceuticals Incorporated Method of treating pain

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11673864B2 (en) 2013-01-31 2023-06-13 Vertex Pharmaceuticals Incorporated Pyridone amides as modulators of sodium channels

Also Published As

Publication number Publication date
NZ750187A (en) 2020-09-25
RS61503B1 (sr) 2021-03-31
HUE053448T2 (hu) 2021-06-28
US20180016235A1 (en) 2018-01-18
SI2953931T1 (sl) 2017-08-31
EP2953931A1 (en) 2015-12-16
JP2021001232A (ja) 2021-01-07
UA120589C2 (uk) 2020-01-10
SMT201700256T1 (it) 2017-09-07
CN108164457B (zh) 2021-07-09
KR20210029848A (ko) 2021-03-16
UY35288A (es) 2014-08-29
JP2018104453A (ja) 2018-07-05
TWI714967B (zh) 2021-01-01
US10738009B2 (en) 2020-08-11
PT2953931T (pt) 2017-06-14
RU2015136795A (ru) 2017-03-10
CN108164457A (zh) 2018-06-15
CN105026373B (zh) 2018-03-30
IL269964B1 (en) 2025-09-01
LT3239134T (lt) 2021-02-25
AU2018214105B2 (en) 2020-04-02
RS56015B1 (sr) 2017-09-29
WO2014120808A1 (en) 2014-08-07
DK2953931T3 (en) 2017-06-06
US9393235B2 (en) 2016-07-19
PH12015501661A1 (en) 2015-10-19
IL240195B (en) 2019-10-31
SG11201505953TA (en) 2015-08-28
AP2015008633A0 (en) 2015-07-31
PE20151781A1 (es) 2015-12-02
PL2953931T3 (pl) 2017-09-29
US11673864B2 (en) 2023-06-13
TWI655187B (zh) 2019-04-01
LT2953931T (lt) 2017-07-25
SI3239134T1 (sl) 2021-03-31
WO2014120808A8 (en) 2015-09-11
HUE033370T2 (en) 2017-11-28
EP3865475A1 (en) 2021-08-18
CA2898866A1 (en) 2014-08-07
US9758483B2 (en) 2017-09-12
AU2020204425A1 (en) 2020-07-23
RU2018126184A (ru) 2019-03-12
US20190248745A1 (en) 2019-08-15
SMT202100030T1 (it) 2021-03-15
JP6741704B2 (ja) 2020-08-19
TW201943701A (zh) 2019-11-16
RU2018126184A3 (cg-RX-API-DMAC7.html) 2021-07-26
US20140213616A1 (en) 2014-07-31
US9051270B2 (en) 2015-06-09
HK1217693A1 (en) 2017-01-20
MX2021003687A (es) 2023-01-25
HK1244269A1 (en) 2018-08-03
PT3239134T (pt) 2021-01-28
EP3239134B1 (en) 2020-12-23
CY1119163T1 (el) 2018-02-14
AU2018214105A1 (en) 2018-08-30
BR112015018289A2 (pt) 2017-07-18
SG10201706206PA (en) 2017-08-30
CL2015002147A1 (es) 2016-06-03
WO2014120808A9 (en) 2015-05-14
PE20191495A1 (es) 2019-10-21
IL269964A (en) 2019-11-28
PL3239134T3 (pl) 2021-06-14
CN105026373A (zh) 2015-11-04
AU2018214105B9 (en) 2020-04-23
HRP20210349T1 (hr) 2021-04-16
IL240195A0 (en) 2015-09-24
US10087143B2 (en) 2018-10-02
KR20150112031A (ko) 2015-10-06
DK3239134T3 (da) 2021-02-22
NZ710270A (en) 2020-09-25
US20150246028A1 (en) 2015-09-03
JP2016506963A (ja) 2016-03-07
MX2015009602A (es) 2015-11-25
GEAP201414909A (cg-RX-API-DMAC7.html) 2020-07-10
KR102227592B1 (ko) 2021-03-15
JP2019089861A (ja) 2019-06-13
KR102295748B1 (ko) 2021-09-01
RU2662223C2 (ru) 2018-07-25
TW201443019A (zh) 2014-11-16
MX383688B (es) 2025-03-14
PH12015501661B1 (en) 2020-10-16
AR094667A1 (es) 2015-08-19
GEP20217286B (en) 2021-08-25
CA2898866C (en) 2023-03-07
AU2014212509B2 (en) 2018-05-10
US20170037009A1 (en) 2017-02-09
US20210047271A1 (en) 2021-02-18
EP3239134A1 (en) 2017-11-01
ES2626555T3 (es) 2017-07-25
ES2857687T3 (es) 2021-09-29
GEP20207177B (en) 2020-11-10
EP2953931B1 (en) 2017-03-01
HRP20170787T1 (hr) 2017-08-11
AU2014212509A1 (en) 2015-08-06

Similar Documents

Publication Publication Date Title
JP6389194B2 (ja) ナトリウムチャネルの調節剤としてのピリドンアミド
JP6346622B2 (ja) ナトリウムチャネルの調節剤としてのアミド
JP6362623B2 (ja) ナトリウムチャネルの調節剤としてのキノリンおよびキノキサリンアミド
JP6463580B2 (ja) ナトリウムチャネルの調節剤として有用なピリドンアミドのプロドラッグ
JP6337109B2 (ja) ナトリウムチャネルの調節剤としてのスルホンアミド
RU2808424C2 (ru) Пиридонамиды в качестве модуляторов натриевых каналов
HK1244269B (en) Pyridone amides as modulators of sodium channels
HK1217693B (en) Pyridone amides as modulators of sodium channels

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171120

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180220

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180731

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180816

R150 Certificate of patent or registration of utility model

Ref document number: 6389194

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250